MAINZ BIOMED B.V. MYNZ 深 滬
等待開盤 07-17 09:30:00 美东时间
1.82
-0.160
-8.08%
華盛通- 最 高1.94
- 今 開1.92
- 成交量 11.65万股
- 最 低 1.80
- 昨 收 1.98
- 總市值 694.31万
- 52周最高 19.004
- 市盈率 靜 --
- 換手率 3.05%
- 52周最低 1.3381
- 委 比 92.60%
- 總股本 381.49万
- 歷史最高 1200.00
- 量 比 0.27
- 振 幅 7.07%
- 歷史最低 1.3381
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mainz Biomed Reviews H1 2025 Accomplishments; Plans To Complete eAArly DETECT 2 Feasibility Study In H2 2025.
Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over
07-15 20:09
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Mainz Biomed has made significant strides in advancing its colorectal and pancreatic cancer screening technologies. The company initiated the eAArly DETECT 2 feasibility study for its next-gen CRC test, launched ColoAlert® in Switzerland, and entered collaborations to expand its product portfolio. Additionally, it secured a license for novel mRNA biomarkers for pancreatic cancer detection, with high sensitivity and specificity, and received publi...
07-15 12:01
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Mainz Biomed N.V. has received public funding from the German Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer project. The state will fund up to 50% of the project’s costs, supporting the company’s non-invasive blood-based screening test for early pancreatic cancer detection. The grant emphasizes the project’s medical and technological relevance, aiming to bridge a critical gap in cancer diagnostics by enabling earl...
06-25 12:01
Mainz Biomed Launches Feasibility Phase Of PancAlert Non-Invasive Blood Test For Early Pancreatic Cancer Detection Following 95% Sensitivity And 98% Specificity Results
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commencement of the next phase in its PancAlert
06-10 21:06
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Mainz Biomed启动PancAlert项目新阶段，开发非侵入性血液筛查测试以实现胰腺癌早期检测，验证候选mRNA生物标志物的敏感性和特异性，并计划进一步开展大规模验证研究，为临床应用和监管申报做准备。
06-10 13:01
Mainz Biomed N.V. Secures $4 Million Through Securities Offering
The latest announcement is out from Mainz Biomed B.V. ( ($MYNZ) ). Mainz Biomed...
05-21 19:17
Mainz Biomed prices $4M securities offering
Mainz Biomed (NASDAQ:MYNZ) has priced a follow-on offering of 2M units to raise gross proceeds of approximately $4M. Each unit, consisting of one ordinary share (or pre-funded warrant in lieu thereof)...
05-20 16:38
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Novavax, Inc (NASDAQ:NVAX) rose sharply in today's pre-market after t...
05-19 18:34
Mainz Biomed Files For Offer Of 2.,448,980 Ordinary Units And 2,488,988 Pre-Funded Units
-SEC Filing
05-14 20:55
Mainz Biomed Reports 2024 Financial Success and Strategic Advances
Mainz Biomed B.V. ( ($MYNZ) ) has provided an update. Mainz Biomed N.V. announc...
04-01 20:26
